FDA
-
-
-
-
-
-
-
Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack
-
-
-
-
-
-
-
New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments
-
-
-
-
-
-
-
Bayer to Expand Into Molecular Imaging With Acquisition of Innovative Pan-Amyloid Radiotracers From Attralus
-
-
-
-
-
-
-
KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease
-
-
-
-
-
-
-
Gadoquatrane New Drug Application Accepted for Review by U.S. FDA
322,246 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

